Enhanced in Vivo Efficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis

IFNβ is a common therapeutic option to treat multiple sclerosis. It is unique among the family of type I IFNs in that it binds to the interferon receptors with high affinity, conferring exceptional biological properties. We have previously reported the generation of an interferon superagonist (dubbe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Harari, Daniel, Kuhn, Nadine, Abramovich, Renne, Sasson, Keren, Zozulya, Alla L., Smith, Paul, Schlapschy, Martin, Aharoni, Rina, Köster, Mario, Eilam, Raya, Skerra, Arne, Schreiber, Gideon
Format: Artigo
Jezik:Inglês
Izdano: American Society for Biochemistry and Molecular Biology 2014
Teme:
Immunology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4200257/
https://ncbi.nlm.nih.gov/pubmed/25193661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M114.602474
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items